WO2003066585A3 - Polymer-based compositions for sustained release - Google Patents
Polymer-based compositions for sustained release Download PDFInfo
- Publication number
- WO2003066585A3 WO2003066585A3 PCT/US2003/003981 US0303981W WO03066585A3 WO 2003066585 A3 WO2003066585 A3 WO 2003066585A3 US 0303981 W US0303981 W US 0303981W WO 03066585 A3 WO03066585 A3 WO 03066585A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained release
- polymer
- fsh
- compositions
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03713410A EP1471891A4 (en) | 2002-02-08 | 2003-02-07 | Polymer-based compositions for sustained release |
JP2003565960A JP2005517012A (en) | 2002-02-08 | 2003-02-07 | Polymer-based composition for sustained release |
NZ535008A NZ535008A (en) | 2002-02-08 | 2003-02-07 | Polymer-based compositions for sustained release |
CA002474698A CA2474698C (en) | 2002-02-08 | 2003-02-07 | Polymer-based compositions for sustained release |
AU2003217367A AU2003217367B2 (en) | 2002-02-08 | 2003-02-07 | Polymer-based compositions for sustained release |
IL163218A IL163218A (en) | 2002-02-08 | 2004-07-26 | Polymer-based compositions for sustained release of fsh |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35515902P | 2002-02-08 | 2002-02-08 | |
US60/355,159 | 2002-02-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003066585A2 WO2003066585A2 (en) | 2003-08-14 |
WO2003066585A3 true WO2003066585A3 (en) | 2004-03-11 |
Family
ID=27734472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/003981 WO2003066585A2 (en) | 2002-02-08 | 2003-02-07 | Polymer-based compositions for sustained release |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040028733A1 (en) |
EP (1) | EP1471891A4 (en) |
JP (1) | JP2005517012A (en) |
AU (1) | AU2003217367B2 (en) |
CA (1) | CA2474698C (en) |
IL (1) | IL163218A (en) |
NZ (1) | NZ535008A (en) |
WO (1) | WO2003066585A2 (en) |
ZA (1) | ZA200405852B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
US20050019380A1 (en) * | 2002-04-26 | 2005-01-27 | Xylos Corporation | Microbial cellulose wound dressing for treating chronic wounds |
AU2003277446A1 (en) | 2002-10-17 | 2004-05-04 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
DE602004031096D1 (en) | 2003-03-26 | 2011-03-03 | Egalet As | MORPHINE SYSTEM WITH CONTROLLED RELEASE |
CA2518903C (en) * | 2003-04-02 | 2013-02-05 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
US7090433B2 (en) * | 2003-10-07 | 2006-08-15 | Steve Searby | Underground cable laying apparatus |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
KR101040415B1 (en) | 2004-04-15 | 2011-06-09 | 알케르메스,인코포레이티드 | Polymer-based sustained release device |
EA012205B1 (en) | 2004-05-17 | 2009-08-28 | Арес Трейдинг С.А. | Hydrogel interferon formulations |
ES2418833T3 (en) | 2004-06-01 | 2013-08-16 | Ares Trading S.A. | Stabilized interferon liquid formulations |
US7238974B2 (en) * | 2004-10-29 | 2007-07-03 | Infineon Technologies Ag | Semiconductor device and method of producing a semiconductor device |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
JP5161075B2 (en) * | 2005-06-03 | 2013-03-13 | エガレット エイ/エス | Solid pharmaceutical composition having a first fraction of a dispersion medium and a second fraction of a matrix, wherein the second fraction is first at least partially exposed to gastrointestinal fluid |
KR101105871B1 (en) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | hFSF Aqueous Formulation |
WO2008021133A2 (en) | 2006-08-09 | 2008-02-21 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
WO2008086804A2 (en) * | 2007-01-16 | 2008-07-24 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
NZ580447A (en) | 2007-04-23 | 2011-06-30 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof |
EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
CN101801405A (en) | 2007-08-07 | 2010-08-11 | 先进科技及再生医学有限责任公司 | Be contained in the protein formulations of the GDF-5 in the acidic aqueous solution |
EP2211925A1 (en) * | 2007-10-01 | 2010-08-04 | Université Catholique de Louvain | Scaffolds for follicle transplantation |
CA2709088C (en) * | 2007-12-13 | 2016-02-16 | Biocell Center S.P.A. | Method of collection and preservation of fluids and/or materials, in particular of organic fluids and/or materials containing stem cells, and device employable in such method |
ES2387236T3 (en) | 2007-12-20 | 2012-09-18 | Merck Serono S.A. | Pegylated interferon beta formulations |
US8343140B2 (en) | 2008-02-13 | 2013-01-01 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
JP5599778B2 (en) * | 2008-04-14 | 2014-10-01 | デピュイ・シンセス・プロダクツ・エルエルシー | Liquid buffered GDF-5 formulation |
CN101269215B (en) * | 2008-05-15 | 2011-03-23 | 上海天伟生物制药有限公司 | Glucoprotein incretion composition |
WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
WO2010149169A2 (en) | 2009-06-24 | 2010-12-29 | Egalet A/S | Controlled release formulations |
NZ624569A (en) | 2009-09-28 | 2016-01-29 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
KR101042302B1 (en) * | 2010-12-27 | 2011-06-17 | 위재영 | The housing for exterior imaging device of the vehicle |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
AU2013209620B2 (en) * | 2012-01-19 | 2017-06-15 | Merck Millipore Ltd. | Chromatographic media for storage and delivery of therapeutic biologics and small molecules |
KR20150059167A (en) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | Abuse deterrent pharmaceutical compositions for controlled release |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MX2017015504A (en) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Implant placement and removal systems. |
SG11201810102SA (en) | 2016-05-16 | 2018-12-28 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
IL307966A (en) | 2017-01-03 | 2023-12-01 | Intarcia Therapeutics Inc | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
US11376220B2 (en) * | 2017-06-30 | 2022-07-05 | Therio, LLC | Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548302B1 (en) * | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE634668A (en) * | 1962-07-11 | |||
BE744162A (en) * | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | ENCAPSULATION PROCESS |
DE2010115A1 (en) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Process for the production of micro-granules |
JPS523342B2 (en) * | 1972-01-26 | 1977-01-27 | ||
GB1413186A (en) * | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
CH661206A5 (en) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES. |
US5639639A (en) * | 1983-11-02 | 1997-06-17 | Genzyme Corporation | Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof |
US4923805A (en) * | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
US6217911B1 (en) * | 1995-05-22 | 2001-04-17 | The United States Of America As Represented By The Secretary Of The Army | sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
US5384132A (en) * | 1990-03-20 | 1995-01-24 | Akzo N.V. | Stabilized gonadotropin containing preparations |
IT1250075B (en) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | PHARMACEUTICAL COMPOSITIONS CONTAINING GONADOTROPINE. |
EP1013270A3 (en) * | 1992-12-02 | 2001-03-28 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
FR2744367B1 (en) * | 1996-02-02 | 1999-07-09 | Emperaire Jean Claude | MEDICATIONS FOR OVULATION TRIGGERING |
US6573238B2 (en) * | 1997-11-07 | 2003-06-03 | Chiron Corporation | Method for producing sustained-release formulations |
CN100370967C (en) * | 1999-06-04 | 2008-02-27 | 阿尔萨公司 | Implantable gel compositions and method of mfg. |
US6284283B1 (en) * | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
-
2003
- 2003-02-07 US US10/361,797 patent/US20040028733A1/en not_active Abandoned
- 2003-02-07 JP JP2003565960A patent/JP2005517012A/en active Pending
- 2003-02-07 WO PCT/US2003/003981 patent/WO2003066585A2/en active IP Right Grant
- 2003-02-07 EP EP03713410A patent/EP1471891A4/en not_active Withdrawn
- 2003-02-07 NZ NZ535008A patent/NZ535008A/en not_active IP Right Cessation
- 2003-02-07 AU AU2003217367A patent/AU2003217367B2/en not_active Ceased
- 2003-02-07 CA CA002474698A patent/CA2474698C/en not_active Expired - Fee Related
-
2004
- 2004-07-22 ZA ZA200405852A patent/ZA200405852B/en unknown
- 2004-07-26 IL IL163218A patent/IL163218A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548302B1 (en) * | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
NZ535008A (en) | 2005-09-30 |
AU2003217367B2 (en) | 2005-09-08 |
ZA200405852B (en) | 2005-01-24 |
US20040028733A1 (en) | 2004-02-12 |
AU2003217367A1 (en) | 2003-09-02 |
CA2474698C (en) | 2009-07-21 |
IL163218A (en) | 2009-11-18 |
CA2474698A1 (en) | 2003-08-14 |
WO2003066585A2 (en) | 2003-08-14 |
EP1471891A2 (en) | 2004-11-03 |
JP2005517012A (en) | 2005-06-09 |
EP1471891A4 (en) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003066585A3 (en) | Polymer-based compositions for sustained release | |
DE69614685D1 (en) | AGENT FOR DELAYED RELEASE OF HUMAN GROWTH HORMONE | |
WO2001058474A3 (en) | Microencapsulation and sustained release of biologically active agent | |
RS20070511A (en) | Modified release pharmaceutical compositions and processes thereof | |
RU99117926A (en) | MEDICINAL FORMS AND METHOD OF TREATMENT OF DISORDERS OF MEN'S Erectile Function | |
BR9808888A (en) | Dosage forms and method of improving male erectile dysfunction | |
BR9908893A (en) | Liquid polymeric composition for the controlled release of hydrophobic bioactive substances, and process for the controlled release of a hydrophobic bioactive substance in an animal, including humans | |
WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
JP2003505422A5 (en) | ||
ATE396967T1 (en) | (5-(2-HYDROXY-4-CHLOROBENZOYL)VALERIC ACID AND SALTS THEREOF, AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS CONTAINING THESE COMPOUNDS | |
DE69840495D1 (en) | PHARMACEUTICAL FORM WHICH DELETES RAPID DISPERSION PROPERTIES, METHOD OF USE, AND METHOD FOR THE PRODUCTION THEREOF | |
HU230688B1 (en) | Phentanyl composition for the treatment of acute pain | |
RS36704A (en) | Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility | |
WO2004034975A3 (en) | Sustained release profile modification | |
RU2006147244A (en) | METHOD FOR FORMING QUICKLY DISPERSABLE MEDICINAL FORMS CONTAINING AT LEAST ONE FISH GELATIN, WHICH ARE SELECTED ON THE BASIS OF MOLECULAR MASS | |
IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
DE60211769D1 (en) | A process for the preparation of drug granules, the drug granules and pharmaceutical compositions containing them | |
WO2002034267A8 (en) | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states | |
CA2253377A1 (en) | Pharmaceutical compositions for the sustained release of insoluble active principles | |
EP1389468A4 (en) | Compositions for promoting healing of bone fracture | |
KR20090125748A (en) | Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia | |
CA2529983A1 (en) | Preoperative treatment of post operative pain | |
WO1999051201A1 (en) | Sustained release formulation | |
WO2001028578A3 (en) | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | |
EA200100223A3 (en) | Water dispersed ivermectin dosage form for curing ecto- endoparasitic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004/05852 Country of ref document: ZA Ref document number: 200405852 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163218 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2474698 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003713410 Country of ref document: EP Ref document number: 2003565960 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003217367 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 535008 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2003713410 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 535008 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003217367 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 535008 Country of ref document: NZ |